Europe PMC
open access
CC BY 4.0
Semaglutide reduces proteomic organ-specific biological age across randomized clinical trials
Abstract Semaglutide confers cardiovascular and kidney benefits and reduces all-cause mortality in high-risk populations. Whether biological-age metrics capture these effects and provide mechanistic insight remains unclear. We analyzed proteomics from 10,052 participants across fi
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Biomolecular Markers of Bone Metastasis#1072264
- Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer#902664
- Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer#1124408
- SPSS 31.0 Versus GPT-5.5: Performance Across Core Epidemiological and Non-parametric Statistics in Medicine and Applied Health Sciences.#1091090
- Fibroblast Growth Factor 23 as a Prognostic Biomarker in Post-Myocardial Infarction Outcomes: Influence of Renal Function and Its Modulation by Klotho.#376102
Record · ID 1175112
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive